利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

8 条记录 (耗时 0.018 秒)

    PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OR PREVENTION OF HBV INFECTION
    2.
    发明申请
    PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OR PREVENTION OF HBV INFECTION 审中-公开
    用于治疗或预防HBV感染的药物组合物

    公开(公告)号：US20110160252A1

    公开(公告)日：2011-06-30

    申请号：US12999055

    申请日：2009-06-18

    申请人： Masashi Mizokami ,  Yasuhito Tanaka ,  Masaya Sugiyama ,  Masayuki Sudoh

    发明人： Masashi Mizokami ,  Yasuhito Tanaka ,  Masaya Sugiyama ,  Masayuki Sudoh

    IPC分类号： A61K31/44 ,  C07C229/34 ,  A61K31/195 ,  C07D213/55 ,  A61P31/12

    CPC分类号： A61K31/13 ,  A61K31/165 ,  A61K31/201 ,  A61K31/381 ,  A61K31/405 ,  A61K31/4406 ,  A61K31/4418

    摘要： First, the present inventors assessed the effect of the compound represented by formula (III) below on Huh-7 cells infected with HBV, and demonstrated that the compound alone had an anti-HBV effect in vitro.Formula (III) Then, the present inventors revealed that the HBV replication-suppressing effect of PEG-IFN is enhanced in chimeric mice having a human liver infected with genotype C or A HBV when PEG-IFN is used in combination with the compound represented by formula (III) above. The present inventors also revealed that the HBV replication-suppressing effect of Entecavir is enhanced in chimeric mice having a human liver infected with genotype C HBV (wild-type and Entecavir-resistant strains) when Entecavir is used in combination with the compound represented by formula (III) above. In addition, the present inventors revealed that the compound represented by formula (III) above exerts the anti-HBV effect not only against wild-type HBV strains but also against Entecavir- and/or Lamivudine-resistant HBV strains.

    摘要翻译： 首先，本发明人评估了下述式（III）表示的化合物对HBV感染的Huh-7细胞的作用，并证明该化合物在体外具有抗HBV作用。 式（III）然后，本发明人揭示了当将PEG-IFN与由下列化合物组合使用时，将具有基因型C或A HBV感染的人肝的嵌合小鼠中的PEG-IFN的HBV复制抑制作用增强 上述式（III）。 本发明人还发现，当恩替卡韦与式（I）表示的化合物组合使用时，恩替卡韦的HBV复制抑制作用在具有感染基因型C HBV（野生型和恩替卡韦抗性菌株）的人肝脏的嵌合小鼠中得到增强 （三）。 此外，本发明人发现，上述式（III）表示的化合物不仅对抗野生型HBV株而且对依替卡韦和/或拉米夫定耐药的HBV株产生抗HBV作用。

    Beam mislanding correcting system for color cathode ray tube
    5.
    发明授权
    Beam mislanding correcting system for color cathode ray tube 失效
    用于彩色阴极射线管的波束补偿校正系统

    公开(公告)号：US3950671A

    公开(公告)日：1976-04-13

    申请号：US451306

    申请日：1974-03-14

    申请人： Koji Ichigaya ,  Hiromasa Machida ,  Masayuki Sudoh ,  Masami Mizuno ,  Yoriyoshi Awata

    发明人： Koji Ichigaya ,  Hiromasa Machida ,  Masayuki Sudoh ,  Masami Mizuno ,  Yoriyoshi Awata

    IPC分类号： H01J29/02 ,  H01J29/00 ,  H01J29/70 ,  H01J29/72 ,  H04N9/28 ,  H01J29/76

    CPC分类号： H01J29/706 ,  H01J29/006

    摘要： A system for compensating for mislanding of electron beams on the screen of a color cathode ray tube as a result of thermal expansion of a beam selecting structure in the tube comprises electromagnetic devices provided on the tube for producing respective magnetic fields by means of a current supplied thereto so as to change the paths of the electron beams passing through the beam selecting structure, and a circuit for supplying to the electromagnetic devices a current varying in response to a difference between the temperature of the beam selecting structure and the ambient temperature about the tube. The circuit for supplying a current to the electromagnetic devices may desirably include two temperature responsive elements, such as, variable resistors, respectively responding to variations in the temperature of the beam selecting structure and to variations in the ambient temperature about the tube, and preferably being connected in series across a voltage source with a connection point between the variable resistors being connected to the base electrode for controlling the current flowing through the collector-emitter path of the transistor to the electromagnetic devices.

    Compound having anti-hcv activity and process for producing the same
    8.
    发明申请
    Compound having anti-hcv activity and process for producing the same 有权
    具有抗hcv活性的化合物及其制备方法

    公开(公告)号：US20060194870A1

    公开(公告)日：2006-08-31

    申请号：US10563089

    申请日：2004-07-09

    申请人： Masayuki Sudoh ,  Takuo Tsukuda ,  Miyako Masubuchi ,  Kenichi Kawasaki ,  Takeshi Murata ,  Fumio Watanabe ,  Hiroshi Fukuda ,  Susumu Komiyama ,  Tadakatsu Hayase

    发明人： Masayuki Sudoh ,  Takuo Tsukuda ,  Miyako Masubuchi ,  Kenichi Kawasaki ,  Takeshi Murata ,  Fumio Watanabe ,  Hiroshi Fukuda ,  Susumu Komiyama ,  Tadakatsu Hayase

    IPC分类号： A61K31/385 ,  A61K31/335

    CPC分类号： A61K31/195 ,  A61K31/216 ,  A61K31/405 ,  C07C235/76

    摘要： The object of the present invention is to provide a compound useful for the prevention and treatment of viral infectious diseases, and particularly liver diseases caused by HCV infection due to its having a high degree of replication inhibitory activity against HCV, its production method, an intermediate compound useful for its production and a pharmaceutical composition containing these compounds, and the present invention relates to a compound represented by the formula (I): (wherein A represents —(CH2)n—, etc.; B represents —(C═O)—, etc.; D represents —(CH2)m—R′, etc.; E represents a hydrogen atom, etc.; G represents —(CH2)p-J, etc.; bond Q represents a single bond or double bond; and R1, R2 and R3 may be the same or different and each represent a hydrogen atom, etc.), a prodrug thereof or a pharmaceutically acceptable salt thereof.

    摘要翻译： 本发明的目的是提供一种可用于预防和治疗病毒感染性疾病的化合物，特别是由于其对HCV具有高复制抑制活性的HCV感染引起的肝脏疾病，其制备方法，中间体 可用于其生产的化合物和含有这些化合物的药物组合物，本发明涉及由式（I）表示的化合物：其中A表示 - （CH 2 2）n < /等等; B表示 - （CO） - 等; D表示 - （CH 2 2）m -R 1等; E表示 氢原子等; G表示 - （CH 2 CH 2）n -J等;键Q表示单键或双键; R' R 1，R 2和R 3可以相同或不同，各自表示氢原子等），其前药或药学上可接受的盐 其中。